Tom Mirga
Editor at Large
The Biden administration this afternoon proposed amending the 340B statute to let federal health officials audit 340B covered entities “to determine how net income from purchases under [340B] are used by the covered entity.”
The proposed legislation is included in
… Tom Mirga
Editor at Large
A federal district judge in Indianapolis late this afternoon declined to temporarily restrain federal health officials from requiring drug maker Eli Lilly, based on a May 17 enforcement letter, to provide 340B discounts on drugs dispensed by contract pharmacies. Nonetheless,
… Tom Mirga
Editor at Large
Drug makers Sanofi and Novo Nordisk and the federal government filed briefs Tuesday and Wednesday in federal district court in New Jersey in those two manufacturers’ separate challenges to the contract pharmacy requirements.
Sanofi and Novo Nordisk are seeking emergency
… Tom Mirga
Editor at Large
Federal judges in Delaware and Indiana will hear arguments today in drug manufacturers’ AstraZeneca and Eli Lilly’s separate lawsuits challenging the 340B contract pharmacy requirements.
A judge in Wilmington, Del., earlier this week denied AstraZeneca’s motion for an emergency stay
… Tom Mirga
Editor at Large
Vermont’s legislature has voted to bar pharmacy benefit managers (PBMs) from requiring claims modifiers on 340B-purchased drugs, except for claims paid directly or indirectly by Medicaid.
PBMs also would be unable to restrict 340B contract pharmacies’ access to pharmacy networks
… Tom Mirga
Editor at Large
Robert Charrow—the U.S. Health and Human Services (HHS) general counsel who memorably opined that drug companies must offer their products at or below the 340B ceiling price “be it the lunar surface, low-earth orbit, or a neighborhood pharmacy”—has rejoined his
… Tom Mirga
Editor at Large
Tom Mirga
Editor at Large
Pharmaceutical Research and Manufacturers of America (PhRMA) has asked a federal judge to invalidate a federal regulation that would require drug makers, starting in January 2023, to include the full value of patient financial assistance in their Medicaid best price
… Tom Mirga
Editor at Large
Correction, Tuesday, May 25, 4:50 p.m. ET – Earlier today, we reported that the wholesale acquisition price for some of the generic PrEP products is now less than $30 per pill. The correct price is less than $30 per
×
*Sign up for news summaries and alerts from 340B Report
